Dynavax Technologies Corporation (DVAX) Releases Earnings Results, Beats Estimates By $0.15 EPS
Dynavax Technologies Corporation (NASDAQ:DVAX) posted its quarterly earnings data on Friday. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.53) by $0.15, Bloomberg Earnings reports. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. The company had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.28 million. During the same quarter in the prior year, the company posted ($0.90) EPS. The company’s quarterly revenue was down 68.8% compared to the same quarter last year.
Dynavax Technologies Corporation (NASDAQ DVAX) traded down $0.20 on Friday, reaching $21.60. 1,396,470 shares of the company were exchanged, compared to its average volume of 1,408,759.
A number of research analysts have recently commented on the stock. Cowen and Company reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Dynavax Technologies Corporation in a research note on Thursday, August 10th. Zacks Investment Research raised shares of Dynavax Technologies Corporation from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research note on Monday, July 10th. BidaskClub downgraded shares of Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. William Blair reissued an “outperform” rating and set a $30.00 target price on shares of Dynavax Technologies Corporation in a research report on Wednesday, August 9th. Finally, J P Morgan Chase & Co raised shares of Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $6.00 to $27.00 in a research report on Monday, July 31st. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Dynavax Technologies Corporation currently has a consensus rating of “Buy” and an average price target of $25.00.
Dynavax Technologies Corporation Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.